PhotoQ3 Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 5

Employees

  • Latest Deal Type
  • Seed

  • Latest Deal Amount
  • $1.78M

  • Investors
  • 2

PhotoQ3 General Information

Description

Developer of a biopharmaceutical technology designed to cure cancer in a more gentle way for the body. The company's technology conducts business activities under the management philosophy of contributing to patients and society with a method that combines physical energy, biospecific binding and toxins, enabling users to create a synergistic effect and also making it possible to control the extent of treatment and minimize side effects.

Contact Information

Website
www.photoq3.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 3-5-4 Kojimachi
  • B-1, Kojimachi Intelligent Building
  • Tokyo, Chiyoda-ku 102-0084
  • Japan
Primary Industry
Biotechnology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 3-5-4 Kojimachi
  • B-1, Kojimachi Intelligent Building
  • Tokyo, Chiyoda-ku 102-0084
  • Japan

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

PhotoQ3 Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Seed Round 14-Jan-2022 $1.78M Completed Generating Revenue
1. Accelerator/Incubator Completed Startup
To view PhotoQ3’s complete valuation and funding history, request access »

PhotoQ3 Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Class A preferred
To view PhotoQ3’s complete cap table history, request access »

PhotoQ3 Patents

  • 23

    Total Documents Applications and Grants

  • Total Patents Families

  • 5

    Granted

  • 10

    Pending

  • Expiring in next 12 mo

PhotoQ3 Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20240316203-A1 Medicament for killing tumor cells Pending 24-Sep-2021
US-20250000998-A1 Medicament for killing tumor cells Pending 24-Sep-2021
EP-4406556-A1 Medicine for killing tumor cells Inactive 24-Sep-2021
EP-4406556-A4 Medicine for killing tumor cells Inactive 24-Sep-2021
WO-2023048231-A1 Medicine for killing tumor cells Inactive 24-Sep-2021 A61K47/6891
To view PhotoQ3’s complete patent history, request access »

PhotoQ3 Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

PhotoQ3 Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
DEFTA Partners Venture Capital Minority
LINK-J Accelerator/Incubator
To view PhotoQ3’s complete investors history, request access »

Ready to get started?

Request a free trial

PhotoQ3 FAQs

  • When was PhotoQ3 founded?

    PhotoQ3 was founded in 2019.

  • Where is PhotoQ3 headquartered?

    PhotoQ3 is headquartered in Tokyo, Japan.

  • What is the size of PhotoQ3?

    PhotoQ3 has 5 total employees.

  • What industry is PhotoQ3 in?

    PhotoQ3’s primary industry is Biotechnology.

  • Is PhotoQ3 a private or public company?

    PhotoQ3 is a Private company.

  • What is the current valuation of PhotoQ3?

    The current valuation of PhotoQ3 is .

  • What is PhotoQ3’s current revenue?

    The current revenue for PhotoQ3 is .

  • How much funding has PhotoQ3 raised over time?

    PhotoQ3 has raised $1.78M.

  • Who are PhotoQ3’s investors?

    DEFTA Partners and LINK-J have invested in PhotoQ3.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process